Full Press Release Details
BridgeBio Pharma Announces Positive Phase 2 Data For Infigratinib In Children With Achondroplasia.
BBIO
BridgeBio Pharma Announces Positive Phase 2 Data For Infigratinib In Children With Achondroplasia
Key Takeaway: BridgeBio Pharma Announces Positive Phase 2 Data For Infigratinib In Children With Achondroplasia
Price reaction · baseline $10.87 (2023-03-03 close) · 1 other BBIO headline(s) in the window, move may be shared
day 0 close
+52%
day 1 · peak
+70.7%
day 3
+42%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis